Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dublin, Ireland—May 7, 2021—Prothena Corporation plc (NASDAQ:PRTA) announced the hiring of two new employees, accompanied by the grant of options to purchase 155,000 ordinary shares at an exercise price of $27.04, based on the closing price on May 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dublin, Ireland—May 7, 2021—Prothena Corporation plc (NASDAQ:PRTA) announced the hiring of two new employees, accompanied by the grant of options to purchase 155,000 ordinary shares at an exercise price of $27.04, based on the closing price on May 3. The options, part of the 2020 Employment Inducement Incentive Plan, will vest over four years, with a quarter vesting after one year and the rest monthly thereafter. Prothena focuses on developing therapeutics for rare peripheral amyloid and neurodegenerative diseases, leveraging extensive scientific expertise.
Positive
- Prothena is expanding its workforce, indicating growth and development.
- The grant of stock options aligns employee incentives with shareholder interests.
Negative
- None.
Details
News Market Reaction – PRTA
The recorded move for PRTA in the trading session of this news was -5.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland, May 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring two new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 155,000 ordinary shares of the Company. The options have an exercise price per share equal to
About Prothena
Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
Contacts:
Media & Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.